The USC School of Pharmacy has a longstanding history as an innovator in graduate education. Its highly-respected PhD programs in Molecular Pharmacology and Toxicology (MPTX), Pharmaceutical Sciences (PSCI) and Clinical and Experimental Therapeutics (CXPT) have yielded graduates who are placed in leadership positions in academia, the pharmaceutical industry, government and regulatory agencies. Just this year, we launched the Pharmaceutical & Translational Sciences (PHTS) umbrella program, unifying Molecular Pharmacology and Toxicology, Pharmaceutical Sciences and Clinical and Experimental Therapeutics. In this new structure, entering doctoral students attend courses and seminars together and rotate through laboratories across all three programs during their first year.
The USC School of Pharmacy was the first in the nation to offer a PhD program in Pharmaceutical Economics and Policy (PEP), now called Health Economics (HE), more than 19 years ago. Master’s students may pursue Pharmaceutical Economics and Policy or Healthcare Decision Analysis while undergraduates may elect to complete a Progessive MS in Health Economics.
We started the MS in Regulatory Sciences 15 years ago. This venture has grown tremendously as a hybrid model merging traditional classroom and distance programs that provide unique training opportunities to new graduates as well as working professionals. In addition, we recently initiated the first professional doctorate in Regulatory Sciences (DRSc) and two new master’s degrees in Management of Drug Development (MDD) and Medical Product Quality (MPQ).
In addition to our well-established research and training programs, the USC School of Pharmacy is a partner school in the Leonard D. Schaeffer Center for Health Policy & Economics, an internationally recognized leader in the transformation of healthcare through evidence-based policy solutions. The International Center for Regulatory Science and the USC-Taiwan Center for Translational Research, both based at the School of Pharmacy, pursue progressive solutions in pharmaceutical and medical device regulatory issues and translational cancer research respectively. Together, these activities illustrate the School’s commitment to pursuing the highest standards of research, within an interactive training environment that exposes graduate and professional students to the full spectrum of competencies in every aspect of therapeutic development from drug discovery, delivery, and mechanism to translation and clinical testing, regulatory science, outcomes analysis and policy development.